medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2004, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2004; 3 (1)


A concise and structured review of drug-induced toxic hepatic disease

Sierra AF, Torres PD

Idioma: Ingles.
Referencias bibliográficas: 22
Paginas: 18-25
Archivo PDF: 108.70 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clinical Trials 1996; 17: 1-12.

  2. Sackett DL, Straus SH E, Richardson WS, et al: Harm, In: Evidence-Based Medicine. How to practice and teach EBM. Second Edition, Chrchill Livingstone 2000: 155-168.

  3. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-1259.

  4. Stephens MDB. Definitions and classifications of adverse reaction terms. In: Stephens MDB; Talbot JCC; Routledge PA eds, The detection of new adverse reactions. 4th ed, London: Macmillan Reference, 1998: 32-44.

  5. Farrell GC. Drug-Induced liver Disease. Edinburgh, Churchill Livingstone, 1994.

  6. Zimmerman J, Ishak K. General Aspects of Drug-Induced Liver Disease. Gastroenterology Clinics of North America 1995; 24: 739-757.

  7. Benhamou JP. Drug-induced hepatitis: Clinical aspects. In Fillastre JP (ed): Hepatotoxicity of Drugs. Rousen, Universite de Roun, 1986: 23-30.

  8. Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Disease 1970; 3: 282-298.

  9. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Safety 2001; 24: 483-490.

  10. Garcia Rodriguez LA, Gutthann SP, Walker AM, et al. The role of non-steroidal anti-inflammatory drugs in acute liver injury. Br Med J 1992; 305: 865-870.

  11. Larrey D, Vital T, Babany G, et al: Hepatitis associated with Amoxycillin-clavulanic acid combination: Report of 15 cases. Gut 1992; 33: 368-71

  12. Kleinbaum DG, Sullivan KM, Barker ND. Measures of disease frequency. In ActivEpi companion text book. Springer-Verlag. 2003: 67-102.

  13. Black M. Drug-Induced liver disease. In: Clinics in Liver Disease,1998; 23: 483-606.

  14. Guttmacher AE, Collins FS. Genomic Medicine- A Primer. N Eng J of Med 2003; 347: 1512-1520.

  15. Evans WE, McLeod, Drug-Therapy: Pharmacogenomics 2003; 348: 538-549.

  16. Kaplowitz N. Drug-induced Hepatocellular Injury and Cholestasis. Syllabus, AASLD 2003: 79-86.

  17. Gordis L. From Association to Causation: Deriving Inferences from Epidemiologic Studies. In: Epidemiology. Second Edition. WB Saunders Company. 2002: 184-203.

  18. Benichou C, Dannan G. A new method for drug causality assessment: RUCAM. In: Chistian B, ed. Adverse Drug Reactions. A Practical guide to Diagnosis and Management. Chistester: John Wily & Sons Ltd, 1994: 277-283

  19. Mallat A, Dhumeaux D. Cocaine and the liver. J Hepatology 1991; 12: 275-84.

  20. Perino LE, Warren GH, Levine JS. Cocaine-Induced hepatotoxicity in humans. Gastroenterology 1987; 93: 176-182.

  21. Dykuizen RS, Brunt PW, Atkinson P et al. Ecstasy Induced hepatitis mimicking viral hepatitis. Gut 1995; 36: 939-42.

  22. Roenigk HH. Jr. Liver toxicity of retinoid therapy. Am Ac of Dermatology 1988: 19199-205.




2020     |     www.medigraphic.com